CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Galcanezumab

Galcanezumab

The CGRP monoclonal antibody, Emgality (galcanezumab), was approved for the prevention of migraine in adults in September 2018 and, in June 2019, became the first and only anti-CGRP therapy to be approved for the prevention of episodic cluster headache in adults. These approvals were supported by data including the results of the EVOLVE 1 and 2 trials in episodic migraine, the REGAIN trial in chronic migraine and a Phase 3 study in cluster headache. The CONQUER trial investigated the efficacy of galcanezumab in patients with migraine who had failed on 2-4 previous preventive therapies.


Download slideset »


« back to Slides